Trial Profile
OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Avoralstat (Primary)
- Indications Hereditary angioedema
- Focus Therapeutic Use
- Acronyms OPuS-2
- Sponsors BioCryst Pharmaceuticals
- 24 Apr 2018 Results (n=110) assessing the safety and efficacy of an oral treatment, BCX4161, in preventing acute attacks in subjects with hereditary angioedema (HAE), were published in the Allergy.
- 15 Feb 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 08 Feb 2016 Results published in a BioCryst media release.